Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

ded our original expectation for enhancing ApoA-l production in humans," stated Donald J. McCaffrey, President and CEO of Resverlogix. "We know that the enhancement of ApoA-l and key RCT particles in the body is widely recognized by international experts as the necessary markers to potentially impact atherosclerosis regression. Hence, we have achieved another critically important clinical milestone for our Company," noted McCaffrey.

The Phase 1b/2a trial was a double blind safety and tolerance study which investigated the pharmacokinetics and also early pharmacodynamics effects of RVX-208. A total of 72 subjects enrolled in the trial. The study had three arms, a low dose arm with 24 subjects, a dose-escalation arm with 24 subjects, and a third high dose arm with 24 subjects. This trial also examined early markers for reverse cholesterol transport such as ApoA-l, HDL-c, pre-beta HDL and alpha HDL subparticles. Approximately half of the subjects had low levels of baseline HDL cholesterol.

Highlights from the study are as follows:

    -   The primary endpoint, plasma ApoA-I increase compared to placebo,
        achieved a range in all subjects of 5.1% - 10.4% in all doses at days
        8 and 28 respectively.
    -   At the lowest dose of 1mg/kg b.i.d. in subjects with low levels of
        HDL-c, plasma ApoA-l increases reached statistical significance of
        5.7% (p(less than)0.05) at day 8 and 7.8% (p(less than)0.05) at
        day 28.
    -   A critical RCT functionality marker, alpha-1 HDL particles,
        illustrated highly statistical significance with an increase of
        46.7% (p(less than)0.004), in all subjects and
        57.2% (p(less than)0.02) in the low dose arm over placebo at day 28.
    -   Pharmacokinetic parameters of RVX-208 were dose dependant with oral
        administration.
    -   RVX-208 was shown to be compatible with simvastatin (40mg).
    -   Seventy out of seventy two subjects completed the tria
'/>"/>
Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... , June 29, 2015   Veracyte, Inc . ... the field of molecular cytology, today announced that it ... prestigious Top Workplaces list for the second year in ... based solely on an annual survey of Bay Area-company ... that the degree to which Veracyte values our employees ...
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
(Date:6/26/2015)... 23, 2015 Research ... of the "Global Cancer Biosimilars Market Opportunity ... Market introduction of cancer biosimilar is required because ... Chemotherapeutic drugs have dominated the cancer segment for ... introduced in past few years. They are biologic ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3
... trees pull vast amounts of water from their roots up ... capillary action, but now scientists at the University of Rochester ... using the same principlebut does so at a speed that ... upcoming issue of Applied Physics Letters , may prove ...
... (Nasdaq: VPHM ) today announced that Colin Broom, ... present at the 30th Annual Goldman Sachs Global Healthcare Conference ... The conference is being held at the Grand Hyatt in ... William Roberts, vice president, corporate communications will present at the ...
... BASKING RIDGE, N.J., June 2 Regado Biosciences, Inc., ... therapeutic aptamers with active control agents, today announced the ... MAB is comprised of leaders in the fields of ... highly regarded leaders will advise the Company on its ...
Cached Biology Technology:Scientists create metal that pumps liquid uphill 2Scientists create metal that pumps liquid uphill 3ViroPharma to Present at Two June Healthcare Conferences 2Regado Biosciences Establishes Medical Advisory Board 2Regado Biosciences Establishes Medical Advisory Board 3
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
(Date:6/8/2015)...  The Secure Identity & Biometrics Association ... Troy Potter of L-3 National Security Solutions ... non-profit association that was established in February 2014 ... of solutions that protect and secure identity across ... Photo - ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... of our daily vocabulary. We all know they,re part of ... We know they have something to do with starches and ... a lot for science to learn about them. ... Nikki Pohl, an Iowa State University associate professor of chemistry. ...
... UC Davis Cancer Center shows that a protein called Muc4 ... spread to other organs and resist therapeutic treatment. The study, ... Research , is one of the first to characterize the ... author of the study, knew that Muc4 was not always ...
... worldwide trade organisation bringing together users and manufacturers of ... Cavimeter was judged by the panel to be "more ... culmination of a period of research, development and exploitation ... Acoustic cavitation is the inception, growth and eventual collapse ...
Cached Biology News:Iowa State chemist synthesizes carbohydrates, launches startup company 2UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs 2NPL Cavimeter receives 2009 UIA Outstanding Product Award 2
...
... 500 optimization kit is for fine-tuning the ... The kit is recommended when you are ... The kit includes 0.25 g each of ... diameter gold microcarriers, 100 each of 9 ...
... is specifically designed for two-dimensional electrophoresis ... four proteins in this marker have ... pattern across a 2D gel. The ... Mol wt: 17,000-89,000 ...
... Blocker Arrays can be used to test ... proteins and sera that are commonly used ... array contains spots for 21 different protein ... of antibody crossreactivity and species specificity, QC ...
Biology Products: